Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 101 entries
Sorted by: Best Match Show Resources per page
Vilazodone for the Treatment of Depression: An Update.

Chonnam medical journal

Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Pae CU.
PMID: 27231672
Chonnam Med J. 2016 May;52(2):91-100. doi: 10.4068/cmj.2016.52.2.91. Epub 2016 May 20.

Vilazodone is a novel antidepressant having a selective serotonin (5-HT) reuptake inhibitor and 5-HT1A receptor partial agonist profile, so it has been regarded as a serotonin partial agonist-reuptake inhibitor (SPARI). We aimed to provide Vilazodone's clinical implications mainly by...

Cite
Wang SM, Han C, Lee SJ, et al. Vilazodone for the Treatment of Depression: An Update. Chonnam Med J. 2016;52(2):91-100doi: 10.4068/cmj.2016.52.2.91.
Wang, S. M., Han, C., Lee, S. J., Patkar, A. A., Masand, P. S., & Pae, C. U. (2016). Vilazodone for the Treatment of Depression: An Update. Chonnam medical journal, 52(2), 91-100. https://doi.org/10.4068/cmj.2016.52.2.91
Wang, Sheng-Min, et al. "Vilazodone for the Treatment of Depression: An Update." Chonnam medical journal vol. 52,2 (2016): 91-100. doi: https://doi.org/10.4068/cmj.2016.52.2.91
Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Pae CU. Vilazodone for the Treatment of Depression: An Update. Chonnam Med J. 2016 May;52(2):91-100. doi: 10.4068/cmj.2016.52.2.91. Epub 2016 May 20. PMID: 27231672; PMCID: PMC4880584.
Copy Download .nbib Format: NLM
Meta-analysis of 38 placebo-controlled studies examining the antidepressant-induced analgesic effect.

Acta neuropsychiatrica

Onghena P, van Houdenhove B.
PMID: 26952554
Acta Neuropsychiatr. 1990 Dec;2(4):85-94. doi: 10.1017/S0924270800034499.

For all controlled studies that bear upon the analgesic-effect of antidepressants, a meta-analysis was conducted to get an estimation of the effect size and to get a sight on the possible modes of action. For this purpose both content...

Cite
Onghena P, van Houdenhove B. Meta-analysis of 38 placebo-controlled studies examining the antidepressant-induced analgesic effect. Acta Neuropsychiatr. 1990;2(4):85-94doi: 10.1017/S0924270800034499.
Onghena, P., & van Houdenhove, B. (1990). Meta-analysis of 38 placebo-controlled studies examining the antidepressant-induced analgesic effect. Acta neuropsychiatrica, 2(4), 85-94. https://doi.org/10.1017/S0924270800034499
Onghena, P, and van Houdenhove, B. "Meta-analysis of 38 placebo-controlled studies examining the antidepressant-induced analgesic effect." Acta neuropsychiatrica vol. 2,4 (1990): 85-94. doi: https://doi.org/10.1017/S0924270800034499
Onghena P, van Houdenhove B. Meta-analysis of 38 placebo-controlled studies examining the antidepressant-induced analgesic effect. Acta Neuropsychiatr. 1990 Dec;2(4):85-94. doi: 10.1017/S0924270800034499. PMID: 26952554.
Copy Download .nbib Format: NLM
Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update.

Chonnam medical journal

Wang SM, Han C, Lee SJ, Jun TY, Patkar AA, Masand PS, Pae CU.
PMID: 27689026
Chonnam Med J. 2016 Sep;52(3):159-72. doi: 10.4068/cmj.2016.52.3.159. Epub 2016 Sep 23.

Less than one third of patients who suffer from major depressive disorder (MDD) report remission following antidepressant treatments requiring more diverse treatment approaches. Augmentation of second generation antipsychotics (SGAs) has been increasingly recognized as an important treatment option. The...

Cite
Wang SM, Han C, Lee SJ, et al. Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update. Chonnam Med J. 2016;52(3):159-72doi: 10.4068/cmj.2016.52.3.159.
Wang, S. M., Han, C., Lee, S. J., Jun, T. Y., Patkar, A. A., Masand, P. S., & Pae, C. U. (2016). Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update. Chonnam medical journal, 52(3), 159-72. https://doi.org/10.4068/cmj.2016.52.3.159
Wang, Sheng-Min, et al. "Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update." Chonnam medical journal vol. 52,3 (2016): 159-72. doi: https://doi.org/10.4068/cmj.2016.52.3.159
Wang SM, Han C, Lee SJ, Jun TY, Patkar AA, Masand PS, Pae CU. Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update. Chonnam Med J. 2016 Sep;52(3):159-72. doi: 10.4068/cmj.2016.52.3.159. Epub 2016 Sep 23. PMID: 27689026; PMCID: PMC5040765.
Copy Download .nbib Format: NLM
The Nordic health registers - an important source when evaluating the safety of antidepressants during pregnancy.

Clinical epidemiology

Kieler H.
PMID: 21042552
Clin Epidemiol. 2010 Oct 21;2:205-7. doi: 10.2147/CLEP.S10426.

Depression during pregnancy occurs frequently and selective serotonin reuptake inhibitors (SSRIs) are often the drug of choice when treating pregnant women. Most published studies found no increased risks of congenital malformations in association with SSRIs, but there are reports...

Cite
Kieler H. The Nordic health registers - an important source when evaluating the safety of antidepressants during pregnancy. Clin Epidemiol. 2010;2:205-7doi: 10.2147/CLEP.S10426.
Kieler, H. (2010). The Nordic health registers - an important source when evaluating the safety of antidepressants during pregnancy. Clinical epidemiology, 2205-7. https://doi.org/10.2147/CLEP.S10426
Kieler, Helle. "The Nordic health registers - an important source when evaluating the safety of antidepressants during pregnancy." Clinical epidemiology vol. 2 (2010): 205-7. doi: https://doi.org/10.2147/CLEP.S10426
Kieler H. The Nordic health registers - an important source when evaluating the safety of antidepressants during pregnancy. Clin Epidemiol. 2010 Oct 21;2:205-7. doi: 10.2147/CLEP.S10426. PMID: 21042552; PMCID: PMC2964074.
Copy Download .nbib Format: NLM
Association analysis between variants of the interleukin-1beta and the interleukin-1 receptor antagonist gene and antidepressant treatment response in major depression.

Neuropsychiatric disease and treatment

Tadić A, Rujescu D, Müller MJ, Kohnen R, Stassen HH, Szegedi A, Dahmen N.
PMID: 18728809
Neuropsychiatr Dis Treat. 2008 Feb;4(1):269-76. doi: 10.2147/ndt.s2262.

This study investigated the possible association of the interleukin-1 beta (IL-1beta) C-511T promoter polymorphism and the interleukin-1 receptor antagonist (IL-1Ra) (86bp)(n) variable number of tandem repeats (VNTR) polymorphism with antidepressant response to paroxetine and mirtazapine treatment. The study group...

Cite
Tadić A, Rujescu D, Müller MJ, et al. Association analysis between variants of the interleukin-1beta and the interleukin-1 receptor antagonist gene and antidepressant treatment response in major depression. Neuropsychiatr Dis Treat. 2008;4(1):269-76doi: 10.2147/ndt.s2262.
Tadić, A., Rujescu, D., Müller, M. J., Kohnen, R., Stassen, H. H., Szegedi, A., & Dahmen, N. (2008). Association analysis between variants of the interleukin-1beta and the interleukin-1 receptor antagonist gene and antidepressant treatment response in major depression. Neuropsychiatric disease and treatment, 4(1), 269-76. https://doi.org/10.2147/ndt.s2262
Tadić, André, et al. "Association analysis between variants of the interleukin-1beta and the interleukin-1 receptor antagonist gene and antidepressant treatment response in major depression." Neuropsychiatric disease and treatment vol. 4,1 (2008): 269-76. doi: https://doi.org/10.2147/ndt.s2262
Tadić A, Rujescu D, Müller MJ, Kohnen R, Stassen HH, Szegedi A, Dahmen N. Association analysis between variants of the interleukin-1beta and the interleukin-1 receptor antagonist gene and antidepressant treatment response in major depression. Neuropsychiatr Dis Treat. 2008 Feb;4(1):269-76. doi: 10.2147/ndt.s2262. PMID: 18728809; PMCID: PMC2515903.
Copy Download .nbib Format: NLM
Ten ways to improve the treatment of depression and anxiety in adults.

Mental health in family medicine

Dunlop BW, Scheinberg K, Dunlop AL.
PMID: 24427185
Ment Health Fam Med. 2013 Sep;10(3):175-81.

Complaints of depression and anxiety are very common among adult patients seeking treatment in primary care settings, and primary care providers prescribe the majority of medications for these conditions. Psychiatrists are often asked to evaluate and manage patients with...

Cite
Dunlop BW, Scheinberg K, Dunlop AL. Ten ways to improve the treatment of depression and anxiety in adults. Ment Health Fam Med. 2013;10(3):175-81
Dunlop, B. W., Scheinberg, K., & Dunlop, A. L. (2013). Ten ways to improve the treatment of depression and anxiety in adults. Mental health in family medicine, 10(3), 175-81.
Dunlop, Boadie W, et al. "Ten ways to improve the treatment of depression and anxiety in adults." Mental health in family medicine vol. 10,3 (2013): 175-81.
Dunlop BW, Scheinberg K, Dunlop AL. Ten ways to improve the treatment of depression and anxiety in adults. Ment Health Fam Med. 2013 Sep;10(3):175-81. PMID: 24427185; PMCID: PMC3822665.
Copy Download .nbib Format: NLM
A cluster model of temperament as an indicator of antidepressant response and symptom severity in major depression.

Psychiatry investigation

Paavonen V, Kampman O, Illi A, Viikki M, Setälä-Soikkeli E, Leinonen E.
PMID: 24605119
Psychiatry Investig. 2014 Jan;11(1):18-23. doi: 10.4306/pi.2014.11.1.18. Epub 2014 Jan 21.

OBJECTIVE: Not enough is known about which patients suffering from major depressive disorder benefit from antidepressant drug treatment. Individual temperament is relatively stable over a person's lifespan and is thought to be largely biologically predefined. We assessed how temperament...

Cite
Paavonen V, Kampman O, Illi A, et al. A cluster model of temperament as an indicator of antidepressant response and symptom severity in major depression. Psychiatry Investig. 2014;11(1):18-23doi: 10.4306/pi.2014.11.1.18.
Paavonen, V., Kampman, O., Illi, A., Viikki, M., Setälä-Soikkeli, E., & Leinonen, E. (2014). A cluster model of temperament as an indicator of antidepressant response and symptom severity in major depression. Psychiatry investigation, 11(1), 18-23. https://doi.org/10.4306/pi.2014.11.1.18
Paavonen, Vesa, et al. "A cluster model of temperament as an indicator of antidepressant response and symptom severity in major depression." Psychiatry investigation vol. 11,1 (2014): 18-23. doi: https://doi.org/10.4306/pi.2014.11.1.18
Paavonen V, Kampman O, Illi A, Viikki M, Setälä-Soikkeli E, Leinonen E. A cluster model of temperament as an indicator of antidepressant response and symptom severity in major depression. Psychiatry Investig. 2014 Jan;11(1):18-23. doi: 10.4306/pi.2014.11.1.18. Epub 2014 Jan 21. PMID: 24605119; PMCID: PMC3942547.
Copy Download .nbib Format: NLM
Effectiveness of pharmaceutical therapy of ADHD (Attention-Deficit/Hyperactivity Disorder) in adults - health technology assessment.

GMS health technology assessment

Benkert D, Krause KH, Wasem J, Aidelsburger P.
PMID: 21289886
GMS Health Technol Assess. 2010 Sep 07;6:Doc13. doi: 10.3205/hta000091.

BACKGROUND: Attention-Deficit/Hyperactivity Disorder (ADHD) is a mental disorder. Symptoms include hyperactivity, lack of attentiveness, and frivolousness. This disorder always begins in childhood, but can remain through adulthood. ADHD affects all areas of life and limits the quality of life...

Cite
Benkert D, Krause KH, Wasem J, et al. Effectiveness of pharmaceutical therapy of ADHD (Attention-Deficit/Hyperactivity Disorder) in adults - health technology assessment. GMS Health Technol Assess. 2010;6:Doc13doi: 10.3205/hta000091.
Benkert, D., Krause, K. H., Wasem, J., & Aidelsburger, P. (2010). Effectiveness of pharmaceutical therapy of ADHD (Attention-Deficit/Hyperactivity Disorder) in adults - health technology assessment. GMS health technology assessment, 6Doc13. https://doi.org/10.3205/hta000091
Benkert, Diana, et al. "Effectiveness of pharmaceutical therapy of ADHD (Attention-Deficit/Hyperactivity Disorder) in adults - health technology assessment." GMS health technology assessment vol. 6 (2010): Doc13. doi: https://doi.org/10.3205/hta000091
Benkert D, Krause KH, Wasem J, Aidelsburger P. Effectiveness of pharmaceutical therapy of ADHD (Attention-Deficit/Hyperactivity Disorder) in adults - health technology assessment. GMS Health Technol Assess. 2010 Sep 07;6:Doc13. doi: 10.3205/hta000091. PMID: 21289886; PMCID: PMC3010888.
Copy Download .nbib Format: NLM
Optimizing the Use of Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: From Clinical Trials to Clinical Practice.

Chonnam medical journal

Han C, Wang SM, Lee SJ, Jun TY, Pae CU.
PMID: 26306301
Chonnam Med J. 2015 Aug;51(2):66-80. doi: 10.4068/cmj.2015.51.2.66. Epub 2015 Aug 17.

Major depressive disorder (MDD) is a recurrent, chronic, and devastating disorder leading to serious impairment in functional capacity as well as increasing public health care costs. In the previous decade, switching therapy and dose adjustment of ongoing antidepressants was...

Cite
Han C, Wang SM, Lee SJ, et al. Optimizing the Use of Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: From Clinical Trials to Clinical Practice. Chonnam Med J. 2015;51(2):66-80doi: 10.4068/cmj.2015.51.2.66.
Han, C., Wang, S. M., Lee, S. J., Jun, T. Y., & Pae, C. U. (2015). Optimizing the Use of Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: From Clinical Trials to Clinical Practice. Chonnam medical journal, 51(2), 66-80. https://doi.org/10.4068/cmj.2015.51.2.66
Han, Changsu, et al. "Optimizing the Use of Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: From Clinical Trials to Clinical Practice." Chonnam medical journal vol. 51,2 (2015): 66-80. doi: https://doi.org/10.4068/cmj.2015.51.2.66
Han C, Wang SM, Lee SJ, Jun TY, Pae CU. Optimizing the Use of Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: From Clinical Trials to Clinical Practice. Chonnam Med J. 2015 Aug;51(2):66-80. doi: 10.4068/cmj.2015.51.2.66. Epub 2015 Aug 17. PMID: 26306301; PMCID: PMC4543152.
Copy Download .nbib Format: NLM
The Present and Future of Precision Medicine in Psychiatry: Focus on Clinical Psychopharmacology of Antidepressants.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology

Serretti A.
PMID: 29397661
Clin Psychopharmacol Neurosci. 2018 Feb 28;16(1):1-6. doi: 10.9758/cpn.2018.16.1.1.

Precision medicine is a concept which is recently gaining momentum in all branches of medicine. In particular in psychiatry it is greatly needed given the huge societal costs of psychiatric disorders and given the long time needed to observe...

Cite
Serretti A. The Present and Future of Precision Medicine in Psychiatry: Focus on Clinical Psychopharmacology of Antidepressants. Clin Psychopharmacol Neurosci. 2018;16(1):1-6doi: 10.9758/cpn.2018.16.1.1.
Serretti, A. (2018). The Present and Future of Precision Medicine in Psychiatry: Focus on Clinical Psychopharmacology of Antidepressants. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology, 16(1), 1-6. https://doi.org/10.9758/cpn.2018.16.1.1
Serretti, Alessandro. "The Present and Future of Precision Medicine in Psychiatry: Focus on Clinical Psychopharmacology of Antidepressants." Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology vol. 16,1 (2018): 1-6. doi: https://doi.org/10.9758/cpn.2018.16.1.1
Serretti A. The Present and Future of Precision Medicine in Psychiatry: Focus on Clinical Psychopharmacology of Antidepressants. Clin Psychopharmacol Neurosci. 2018 Feb 28;16(1):1-6. doi: 10.9758/cpn.2018.16.1.1. PMID: 29397661; PMCID: PMC5810453.
Copy Download .nbib Format: NLM
Advances in Alternative and Integrative Medicine in the Treatment of Depression: A Review of the Evidence.

Archives of Iranian medicine

Shamabadi A, Akhondzadeh S.
PMID: 34196207
Arch Iran Med. 2021 May 01;24(5):409-418. doi: 10.34172/aim.2021.59.

Depression is a chronic and debilitating psychiatric disorder that affects 300 million people worldwide. Pharmacotherapy is one of the treatments. Due to delay in initiating treatment efficacy and the incomplete response to mono-drug therapy in one-third of patients, new...

Cite
Shamabadi A, Akhondzadeh S. Advances in Alternative and Integrative Medicine in the Treatment of Depression: A Review of the Evidence. Arch Iran Med. 2021;24(5):409-418doi: 10.34172/aim.2021.59.
Shamabadi, A., & Akhondzadeh, S. (2021). Advances in Alternative and Integrative Medicine in the Treatment of Depression: A Review of the Evidence. Archives of Iranian medicine, 24(5), 409-418. https://doi.org/10.34172/aim.2021.59
Shamabadi, Ahmad, and Akhondzadeh, Shahin. "Advances in Alternative and Integrative Medicine in the Treatment of Depression: A Review of the Evidence." Archives of Iranian medicine vol. 24,5 (2021): 409-418. doi: https://doi.org/10.34172/aim.2021.59
Shamabadi A, Akhondzadeh S. Advances in Alternative and Integrative Medicine in the Treatment of Depression: A Review of the Evidence. Arch Iran Med. 2021 May 01;24(5):409-418. doi: 10.34172/aim.2021.59. PMID: 34196207.
Copy Download .nbib Format: NLM
Antidepressant use among immigrants with depressive disorder living in Finland: A register-based study.

Journal of affective disorders

Kieseppä V, Markkula N, Taipale H, Holm M, Jokela M, Suvisaari J, Tanskanen A, Gissler M, Lehti V.
PMID: 34953922
J Affect Disord. 2021 Dec 22;299:528-535. doi: 10.1016/j.jad.2021.12.071. Epub 2021 Dec 22.

BACKGROUND: The aim of this study was to examine differences in the initiation and discontinuation of antidepressants between immigrants and the Finnish-born population diagnosed with depression in specialized health care.METHODS: The study utilized register-based data, which includes all immigrants...

Cite
Kieseppä V, Markkula N, Taipale H, et al. Antidepressant use among immigrants with depressive disorder living in Finland: A register-based study. J Affect Disord. 2021;299:528-535doi: 10.1016/j.jad.2021.12.071.
Kieseppä, V., Markkula, N., Taipale, H., Holm, M., Jokela, M., Suvisaari, J., Tanskanen, A., Gissler, M., & Lehti, V. (2021). Antidepressant use among immigrants with depressive disorder living in Finland: A register-based study. Journal of affective disorders, 299528-535. https://doi.org/10.1016/j.jad.2021.12.071
Kieseppä, Valentina, et al. "Antidepressant use among immigrants with depressive disorder living in Finland: A register-based study." Journal of affective disorders vol. 299 (2021): 528-535. doi: https://doi.org/10.1016/j.jad.2021.12.071
Kieseppä V, Markkula N, Taipale H, Holm M, Jokela M, Suvisaari J, Tanskanen A, Gissler M, Lehti V. Antidepressant use among immigrants with depressive disorder living in Finland: A register-based study. J Affect Disord. 2021 Dec 22;299:528-535. doi: 10.1016/j.jad.2021.12.071. Epub 2021 Dec 22. PMID: 34953922.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 101 entries